Free specialist consultation Benefits Separate from GLP-1 mechanism synergy when combined with Ozempic/Mounjaro 22.7% weight loss in CagriSema (REDEFINE-1, 68 weeks) best result among incretin therapies 10.8% in monotherapy over 26 weeks (Phase 2, Lancet 2021) In T2D on metformin: 15.6% weight, 2.2% HbA1c combined with semaglutide Does NOT cause hypoglycemia (unlike insulin and sulfonylureas) Gradual 16-week titration smooth buildup, minimal side effects Convenient weekly dosing half-life ~7 days Cardiovascular risk reduction in T2D (secondary endpoint REDEFINE-2) Alternative/addition for patients plateauing on GLP-1 monotherapy Who it's for Weight plateau on GLP-1 (Ozempic/Mounjaro) adding cagrilintide gives +610% reduction Patients who don't tolerate high GLP-1 doses lower dose + cagrilintide instead of dose increase T2D on metformin better glycemic and weight control than semaglutide-mono Biohackers / advanced users seeking maximum CagriSema protocol effect Post-surgical weight maintenance (bariatric) adjuvant against recidivism Those wanting SEPARATE appetite control mechanism without duplicating GLP-1 How to take Standard 16-week titration (Novo Nordisk Phase 3 CagriSema): Weeks 14: 0.25 mg subcutaneous once weekly
Every dose range below is community-derived from individual-compound research
If you have heart issues or other health conditions, check with your doctor before starting any sauna routine
Monitoring the toxic effects of Pb, Cd and Cu on hematological parameters of Wistar rats and potential protective role of lipoic acid and glutathione
The HFriskT2DM-HScore, integrating clinical variables and NT-proBNP, achieved strong discrimination (C-index 0.81, 95% CI 0.800.83) and calibration (slope 0.93, 95% CI 0.811.1, p = 0.31), enabling targeted screening and early intervention in T2DM patients
Exploring the mechanism of resveratrol in reducing the soft tissue damage of osteoarthritis based on network pharmacology and experimental pharmacology
